Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Randomized, Dose-blind, Multicenter Study to Evaluate the Safety and Efficacy of KZR-616 in the Treatment of Patients With Autoimmune Hemolytic Anemia (AIHA) and Immune Thrombocytopenia (ITP)

NCT04039477 is registered in ClinicalTrials.gov with Kezar Life Sciences, Inc. as lead sponsor.

NCT NCT04039477
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04039477 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Randomized, Dose-blind, Multicenter Study to Evaluate the Safety and Efficacy of KZR-616 in the Treatment of Patients With Autoimmune Hemolytic Anemia (AIHA) and Immune Thrombocytopenia (ITP)
Lead sponsor
Kezar Life Sciences, Inc.
Phase
Phase 2
Overall status
Withdrawn
Start date
July 31, 2020
Completion date
August 5, 2020
Enrollment
0 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

autoimmune hemolytic anemia, immune thrombocytopenia